FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax's partners, all reformulated to target the XFG variant, giving clinicians several options ahead of the fall respiratory virus season.
|Articles|January 6, 2021
Technology Aids in COVID-19 Vaccine Immunity Monitoring
Author(s)Killian Meara
Prior to public vaccination, a rapid and accurate COVID-19 antibody test will help determine the presence of neutralizing antibodies.
Advertisement
An investigator from the University of Alabama at Birmingham (UAB) has recently developed a new technology that has the potential to be used as an in-home antibody test.
The test will aid in immunity monitoring as the coronavirus disease 2019 (COVID-19) vaccines become widely available to the general population. This type of tracking will be important moving forward due to the fact it will help in determining whether the vaccine is effective and for how long in individuals.
Benjamin Larimer, the creator of the diagnostic test and an assistant professor in the UAB Department of Radiology Division of Advanced Medical Imaging Research, broke down the SARS-CoV-2 virus into smaller pieces in order to identify the particular locations of where antibodies attached to it. The findings showed that the test was able to detect positive cases by an increase of 20% in comparison to current standard forms of clinical antibody tests.
This new form is an improvement over contemporary versions because it can help identify specific neutralizing antibodies, which can only be measured at high levels of accuracy now with time-consuming and complicated laboratory tests that the general public does not have access to. Current testing also commonly mistakes antibodies for other viruses leading to higher false-positive results because of the broad approach that they use to locate them.
"The goal of every vaccine is to get the body to produce antibodies, which serve as a first line of defense against the virus," Larimer said. "Tests that specifically detect these antibodies can be used to measure whether a vaccine works, and possibly predict how long its protection will last."
Clinical trials analyzing COVID-19 vaccines have found that they are very successful, however, millions of people will still be unprotected, and immunity monitoring could help to determine the efficacy and if someone is actually protected or not. Larimer plans to continue developing the technology until it is inexpensive and easy for in-home use and has filed a provisional patent application for the test.
Advertisement
Related to this article
The Vaccine Integrity Project, in collaboration with the American Medical Association, conducted a vaccine and immunization effectiveness and safety review for RSV, Influenza, and COVID-19 for the 2026-2027 season. JAMA published the review, and here is an overview of the data going into this year's seasonal respiratory virus season.
The antiviral did not produce greater symptom improvement than placebo in patients with the condition in the RECOVER-VITAL trial.
The FDA has approved formulations for the 2026-2027 vaccines including Pfizer-BioNTech's Comirnaty XFG, Novavax's commercial partners Sanofi and Takeda have secured approvals for its Nuvaxovid, and Moderna's Spikevax and mNEXSPIKE vaccines, all with protections against the currently circulating variant.
The FDA has approved Pfizer-BioNTech's 2026-2027 Comirnaty XFG formula, an updated COVID-19 vaccine targeting the XFG variant, for adults 65 and older and for individuals ages five through 64 with at least one high-risk underlying condition.
Venky Soundararajan, PhD, co-founder and chief scientific officer of nference, explains what the semaglutide-COVID-19/influenza data can and can't tell clinicians about mechanism, bias, and the evidence bar before it should shape prescribing.
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.